Safety and Efficacy Evaluation of IM19 Cells

Hematological Malignancies Clinical Trial

Official title:

Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03344705
• Other study ID #: YMCART201701
• Status: Recruiting
• Phase: Phase 1
• First received: November 14, 2017
• Last updated: November 16, 2017
• Start date: August 21, 2017
• Est. completion date: December 1, 2020

Study information

• Verified date: November 2017
• Source: Beijing Immunochina Medical Science & Technology Co., Ltd.
• Contact: Xin-an Lu, Dr
• Phone: 86-189-1157-6946
• Email: luxinan[@]immunochina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.

Description:

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's lymphoma) and Determine the Best Dosage.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 1, 2020
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with CD19 positive relapsed or refractory B-cell malignancies, including B-cell Acute Lymphocytic Leukemia(ALL)?B-cell Chronic Lymphocytic Leukemia(CLL)?Non-Hodgkin's lymphoma(NHL).

1)Patients with ALL:

• Previously treated with at least two courses of chemotherapy ? The interval of the last chemotherapy and disease progression is less than one year.

? Not suitable for allogeneic stem cell transplantation. 2)Patients with CLL:

• Previously treated with at least two courses of chemotherapy

? The interval of the last chemotherapy and disease progression is less than two years.

? Not suitable for allogeneic stem cell transplantation conditions or due to conditions to abandon allogeneic stem cell transplantation.

3) Patients with DLBCL or FL?PMBCL:

• Patients who relapsed or were refractory after at least two previous treatments.

? Patients who relapsed after transplantation. 4)Patients who have relapsed or have refractory mantle cell lymphoma after at least one treatment.

2.Measurable disease,including minimal residual disease. 3.Gender is not limited, to be aged 4 to 75 years 4.Expected survival >3 months. 5.Eastern Cooperative Oncology Group(ECOG) score 0-2. 6.Women of childbearing potential must have a blood pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.

7.Absence of symptoms of central nervous system(CNS) leukemia.

Exclusion Criteria:

1. Patients who have been treated with chemotherapy or radiotherapy within 2 weeks before blood collection.

2. Patients have GVHD, which needs treatment with immunosuppressive agents,or patients with autoimmune diseases.

3. Patient who have been treated with systemic steroid medication within two weeks of blood collection(Except for the recent or current use of inhaled steroids).

4. Patient who have been treated with stimulation of bone marrow hematopoietic cells generated drugs(Such as Recombinant Human Granulocyte Colony-stimulating Factor Injection) within 2 weeks before the blood collection period to use .

5. The number of T cells in peripheral blood is lower than 2×10^8/L.

6. Previously treatment with any gene therapy products.

7. History of epilepsy or other CNS disease.

8. New York Heart Association(NYHA) grade=?.

9. Creatinine> 1.5×normal value,Alanine transaminase(ALT) /Aspartate aminotransferase(AST)>3×normal value,Bilirubin >2×normal value.

10. Degree of myeloproliferation: ?-V

11. Active hepatitis B , hepatitis C or HIV infection and cytomegalovirus infection ,Epstein-Barr virus infection or any other uncontrolled active infection.

12. Pregnancy or breast-feeding women.

13. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial.

14. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

Related Conditions & MeSH terms

• Hematological Malignancies
• Neoplasms

Intervention

Biological:
• IM19 CAR-T
All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.

Drug:
• Fludarabine
Two days before cell infusion,all patients will be treated with fludarabine for 3 days
• Cyclophosphamide
Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Immunochina Medical Science & Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of study related adverse events	defined as >= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.	2 years
Secondary	Overall response rate	2. Overall response rate An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry	2 years